✦ LIBER ✦

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

✍ Scribed by Suresh S. Ramalingam; R. Donald Harvey; Nabil Saba; Taofeek K. Owonikoko; John Kauh; Dong M. Shin; Shi-Yong Sun; Sandra Strychor; Mourad Tighiouart; Merrill J. Egorin; Haian Fu; Fadlo R. Khuri

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 151 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25264

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

A phase 2 study of cetuximab in combinat

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

✍ Edward S. Kim; Ann M. Mauer; William N. William Jr; Hai T. Tran; Diane Liu; Jack 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

A phase II study of the safety and effic

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

✍ Leena Gandhi; Matthew W. Harding; Marcus Neubauer; Corey J. Langer; Melvin Moore 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views